iShares North American Tech-Multimedia Networking ETF

Gilead Acquires Arcellx in $7.8 Billion Deal to Advance Cancer Therapies Gilead Sciences is set to acquire Arcellx in a deal valued at $7.8 billion, bolstering its oncology pipeline with …